Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Phase 2 Recruiting
153 enrolled
MK-2140-010
Phase 3 Recruiting
1,046 enrolled
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 2 Recruiting
222 enrolled
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Phase 3 Recruiting
1,875 enrolled
MK-2400-001
Phase 3 Recruiting
1,440 enrolled
OCTAGON
Phase 4 Recruiting
75 enrolled
MK-2140-011
Phase 2 Recruiting
594 enrolled
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Phase 2 Recruiting
218 enrolled
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Phase 3 Recruiting
5,951 enrolled
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Phase 2 Recruiting
454 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Phase 1/2 Recruiting
182 enrolled
OLYMPIA-1
Phase 3 Recruiting
822 enrolled
EvoPAR-PR02
Phase 3 Recruiting
700 enrolled
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Phase 2 Recruiting
41 enrolled
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Phase 1 Recruiting
174 enrolled
rechARge
Phase 3 Recruiting
960 enrolled
HO170DLBCL
Phase 3 Recruiting
324 enrolled
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Phase 3 Recruiting
400 enrolled
BRADI
Phase 3 Recruiting
84 enrolled
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Phase 1/2 Recruiting
108 enrolled
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Phase 3 Recruiting
5,000 enrolled
LBL 2018
Phase 3 Recruiting
683 enrolled
PSA-DEEP02
Recruiting
152 enrolled
STELLAR
Phase 2 Recruiting
105 enrolled
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
Phase 2 Recruiting
60 enrolled
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Phase 2 Recruiting
900 enrolled